How Engineered Bacteria Fight Cancer From Inside Tumors

A 130-Year-Old Idea, Reborn

In the 1890s, New York surgeon William B. Coley noticed something strange: some cancer patients who developed bacterial infections saw their tumors shrink. He began injecting patients with heat-killed bacteria — later called "Coley's Toxins" — and documented tumor regressions in sarcomas, melanomas, and lymphomas. The medical establishment largely dismissed his work, but Coley had stumbled onto a principle that synthetic biology is now turning into precision medicine.

Today, researchers are engineering harmless probiotic bacteria to act as microscopic drug factories that infiltrate tumors, sense their environment, and produce cancer-fighting molecules exactly where they are needed. The field is called bacterial cancer therapy, and after decades of setbacks, it is finally gaining serious momentum.

Why Bacteria Love Tumors

Solid tumors create conditions that most therapies struggle to penetrate but bacteria thrive in. Tumors develop abnormal, leaky blood vessels, oxygen-starved (hypoxic) cores, and necrotic tissue — an environment hostile to normal cells but ideal for facultative and obligate anaerobic bacteria such as Salmonella, Clostridium, Bifidobacterium, and Escherichia coli.

Once inside the body, these bacteria naturally home in on tumor tissue, where they can accumulate at concentrations more than 1,000 times higher than in normal organs, according to research published in Experimental & Molecular Medicine. The immunosuppressed microenvironment inside tumors also protects bacteria from being cleared by the immune system, giving them time to colonize and act.

How Engineered Bacteria Work

Modern synthetic biology takes this natural tumor-seeking behavior and supercharges it. Scientists genetically program bacteria with therapeutic "circuits" — stretches of DNA that instruct the microbes to perform specific tasks once they reach a tumor. These engineered functions fall into several categories:

• Drug production: Bacteria are programmed to manufacture and release anti-cancer compounds directly inside the tumor. In a March 2026 study published in PLOS Biology, researchers at Shandong University engineered E. coli Nissle 1917 to produce Romidepsin (FK228), an FDA-approved anti-cancer drug, achieving targeted delivery with reduced systemic side effects.
• Immune activation: Some bacteria are designed to stimulate the immune system by displaying tumor-associated antigens on their surface or by activating the STING pathway, which alerts immune cells to attack. Synlogic's experimental therapy SYNB1891 uses this approach, with preclinical data showing complete tumor rejection in roughly one-third of mice with melanoma.
• Programmed self-destruction: Using quorum-sensing circuits, bacteria can detect when their colony reaches a critical mass, then lyse (burst open) to release their therapeutic cargo all at once — a controlled detonation inside the tumor.

The Clinical Reality

Despite promising animal studies, translating bacterial cancer therapy to humans has proven difficult. The only Salmonella-based therapy to reach a Phase I clinical trial — a strain called VNP20009 — was safely administered to patients with metastatic melanoma and renal carcinoma, and some bacterial colonization was observed in tumor biopsies. However, the anti-tumor effects were disappointing compared to results in mice.

Several challenges remain. Genetic stability is a major concern: engineered DNA circuits can mutate or be lost as bacteria divide inside the body. There are also safety questions about controlling bacterial replication and ensuring the organisms can be eliminated after treatment. Regulatory frameworks for "living medicines" are still evolving, as these therapies do not fit neatly into existing drug categories.

Why It Matters

Conventional chemotherapy floods the entire body with toxic drugs, damaging healthy tissue alongside tumors. Bacterial therapy promises something fundamentally different: a treatment that seeks out cancer on its own, manufactures drugs at the tumor site, and activates the patient's immune system — all while sparing the rest of the body.

With companies like Synlogic advancing clinical programs, academic labs refining genetic circuits, and new studies demonstrating increasingly sophisticated bacterial behaviors, the field is moving closer to making William Coley's century-old observation into a modern cancer weapon. The bacteria, it turns out, were willing partners all along — they just needed better instructions.